New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:07 EDTSRPTSarepta must enhance dataset for acceptable NDA filing, says Janney Capital
Janney Capital noted that the FDA said Sarepta's current dataset is not strong enough alone to file an adequate NDA for eteplirsen for Duchenne Muscular Dystrophy. The FDA suggested a fourth muscle biopsy in Study 202 patients, but Janney believes the company may be challenged to convince patients to undergo such surgeries. The firm maintains its Sell rating and $10 fair value estimate on shares of Sarepta.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
14:47 EDTSRPTDMD drug panelist confirms conflict of interest, Boston Business Journal says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use